Aduro BioTech, Inc. (ADRO) Slides on Pancreatic Cancer Drug Setback

Shares of Berkeley, California, based Aduro BioTech, Inc. (ADRO) fell on Tuesday, against the backdrop of a slightly higher day in stocks overall. Aduro stock was down 16.07%, falling $5.18 per share, to close at $27.05, on volume of 3,387,815 shares. The company's very promising new pancreatic cancer drug was dealt a setback when one of the patients using the drug developed a serious infection.

Founded in 2000, Aduro BioTech, Inc. is a clinical-stage immuno-oncology company, focusing on the development of technology platforms to stimulate an immune response against cancer.
The company has ongoing clinical trials in drug therapies for pancreatic cancer, mesothelioma and high-grade glioma and development programs in non-small cell lung cancer, ovarian cancer and prostate cancer. The company's stock trades on the NASDAQ.

Aduro's pancreatic cancer drug, CRS-207, may have resulted in the development of listeriosis in one patient using the drug. The drug is in Phase 2b testing, and the infection will likely slow the development and marketing of the drug until the exact cause of the infection - as well as its elimination - can be found.

CRS-207 is one of a family of product candidates based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform that induces a potent innate and T cell-mediated adaptive immune response. The drug is engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.

On Monday, Aduro announced that CRS-207 had been granted Orphan Drug Designation in the European Union for the treatment of Mesothelioma.

“The receipt of Orphan Drug Designation in the European Union for CRS-207 for the treatment of MPM marks a significant regulatory milestone for Aduro, as we expand our operations in Europe and advance our therapies closer to the commercial marketplace,” said Aduro Chairman, President and CEO Stephen T. Isaacs, “We look forward to working with the EMA to expeditiously advance CRS-207 through development with the goal of bringing this potential therapy to patients throughout Europe suffering from mesothelioma.”

Also on Monday Aduro reported a third quarter net income of $567,000, or $0.01 per share. Analysts had been expecting a loss of -$0.08 per share. Revenues for the quarter came in at $19.1 million, exceeding analysts expectations of $16.9 million.

Other News ADRO

Aduro Biotech tops Street 3Q forecasts
Aduro Biotech posts third quarter profit, results beat Wall Street estimates.

Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-741 in Prostate Cancer
Phase 1 Clinical Trial now expected to start by year end 2015.

Other Stocks in the News

Apple could make $2.4 billion from iPad Pro in first months
Estimate based on assumption Apple can sell 3 million low-end iPad Pro units, selling at $800 each.

Best Buy downgraded on fears of slowing sales of consumer electronics
RBC Capital Markets downgraded Best Buy Co. to sector perform from outperform over concerns about declining consumer-electronics sales.
Published on Nov 25, 2015
By Kevin Mercadante

Copyrighted 2016. Content published with author's permission.

Posted in ...